Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
The first invasive brain-machine interface medical device approved for market release
Recently, the National Medical Products Administration approved the registration application for an innovative product by Brainsight Medical Technology (Shanghai) Co., Ltd., an implantable brain-computer interface hand movement functional compensation system, achieving the world’s first launch of a brain-computer interface medical device. This marks that the world’s first invasive brain-computer interface medical device has entered the clinical application stage. The product consists of a brain-computer interface implant, an implantable electroencephalogram (EEG) electrode kit, an EEG signal transmitter and receiver, pneumatic glove equipment, a disposable surgical instrument kit, EEG decoding software, medical testing software, and clinical management software. It is suitable for patients with quadriplegia caused by cervical spinal cord injury, and enables hand grasping function compensation assisted by pneumatic glove equipment. Patients must meet the following conditions: aged 18 to 60; quadriplegia with cervical spinal cord injury from C2 to C6 rated A to C; the disease diagnosed for more than 1 year and, after standardized treatment, a stable condition for at least 6 months; unable to complete grasping with the hands, but with some residual function in the upper arm. The product uses minimally invasive extradural implantation and wireless energy supply communication technology. Clinical trial results show that, through this product, subjects achieved a significant improvement in hand grasping ability, thereby improving patients’ quality of life. (CCTV News)